Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants

Poliomyelitis Clinical Trial

Official title:
A Clinical Trial With an Open-label Phase to Evaluate the Safety of Five-dose Sabin Inactivated Poliovirus Vaccine (Vero Cell)（ msIPV） in Adults, Children and Infants, and a Blinded,Randomized and Controlled Phase to Evaluate the Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants

Status Completed

Clinical Trial Summary

This study includes two parts.A clinical trial with a open-label to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml-5 doses)(hereinafter referred to as "msIPV")manufactured by Sinovac Biotech Co., Ltd. in adults, children and infants in partⅠ and a blinded,randomized and controlled clinical trial to evaluate the lot consistency immunogenicity, and safety of the msIPV in 2 months old infants in partⅡ.

Clinical Trial Description

This study includes two stages. A clinical trial with an open-label to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml-5 doses) (hereinafter referred to as "msIPV") in adults, children and infants in stageⅠ and a blinded, randomized and controlled clinical trial to evaluate the lot consistency immunogenicity, and safety of the msIPV in 2 months old infants in stage Ⅱ. A total of 1572 subjects including 24 adults aged 18-49 years,24 children aged 4 years,1524 infants aged 2 months will be enrolled. StagesⅠ:72 healthy subjects, including 24 adults,24 children and 24 infants will be enrolled. 24 adults and 24 children will receive one dose of vaccine and 24 infants will receive 4 doses of vaccine according to the primary immunization schedule of 0,1,2 months and booster immunization schedule of 18 months. StagesⅡ:1500 infants aged 2 months will be randomly divided into 5 groups (Experimental Vaccine-lot 1, Experimental Vaccine-lot 2, Experimental Vaccine-lot 3,IPV control group and single-dose sIPV control group) according to the ratio of 1:1:1:1:1. Subjects in 3 experimental groups will receive 5-dose sIPV produced by Sinovac for three lots, subjects in IPV control group will receive IPV produced by Pasteur, and subjects in single-dose sIPV control group will receive single-dose sIPV produced by Sinovac. All subjects will receive 4 doses of experimental or control vaccine according to the primary immunization schedule of 0,1,2 months, one dose of booster at 18 months of age. ;

Study Design

Related Conditions & MeSH terms

Poliomyelitis

Clinical Trial Details

NCT number	NCT05386810
Study type	Interventional
Source	Sinovac Biotech Co., Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	November 5, 2020
Completion date	July 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04989231` - An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
Completed	`NCT00352963` - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).	Phase 3
Recruiting	`NCT03890497` - Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh	Phase 4
Completed	`NCT00753649` - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants	Phase 4
Completed	`NCT04693286` - Clinical Trial of Novel OPV2 Vaccine	Phase 2
Completed	`NCT02847026` - Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study	Phase 4
Completed	`NCT02189811` - Polio End-game Strategies - Poliovirus Type 2 Challenge Study	Phase 4
Completed	`NCT01444781` - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants	Phase 3
Completed	`NCT01214889` - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.	Phase 3
Completed	`NCT00137696` - Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine	N/A
Completed	`NCT00879827` - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants	Phase 3
Completed	`NCT01457495` - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly	Phase 2
Completed	`NCT02853929` - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Phase 4
Completed	`NCT03614702` - Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV	Phase 3
Terminated	`NCT04063150` - Immunogenicity of Intramuscular and Intradermal IPV	Phase 4
Completed	`NCT04614597` - A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
Completed	`NCT03239496` - A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV	Phase 3
Completed	`NCT04544787` - A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates	Phase 2
Completed	`NCT02985320` - Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine	Phase 1/Phase 2
Completed	`NCT02291263` - Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine	Phase 3